Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond
A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond

April 18th 2025

This shift brings new responsibilities and opportunities, from managing inventory changes to counseling patients on alternative therapies.

Selective focus close up man hand with dry itchy skin conditions peeling texture detail. Old man hand with flaking and cracked allergic dermatitis on his skin - Image credit: CandyRetriever | stock.adobe.com
FDA Grants Interchangeable Designation to Yuflyma for Humira

April 15th 2025

FDA Approved Products or Drugs - Image credit: Olivier Le Moal | stock.adobe.com
FDA Approves Bevacizumab Biosimilar for Various Cancer Types

April 11th 2025

biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book - Image credit: lexiconimages | stock.adobe.com
Organon Expands Portfolio With Biosimilar Tocilizumab-bavi for Arthritis and COVID-19

April 3rd 2025

fda on paper texture - Image credit: Araki Illustrations | stock.adobe.com
Denosumab-bnht Biosimilar Receives FDA Approval

March 27th 2025

<1
...
1617181920